Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Treximet will hit the U.S. market in mid-May, GSK says.
Advertisement

Related Content

Pozen Wins Injunction To Block Par From Launching Generic Migraine Drug Treximet
Short-Selling Reform Is On BIO Wish List For Stimulus Bill
Pozen/AZ Combo Pill Could See Setback As FDA Reviews Trial Endpoints
NeurAxon Focusing On Migraine With Aura For nNOS Inhibitor
NeurAxon To Focus On Migraine With Aura For Potential First-In-Class nNOS Inhibitor
North Carolina Biotech CEOs – A Roundtable Interview With “The Pink Sheet” DAILY, Part 1
North Carolina Biotech CEOs – A Roundtable Interview With “The Pink Sheet” DAILY, Part 1
GSK’s Treximet Could Face Market Headaches
Trexima Approvable Letter Another Headache For Pozen
Trexima Approvable Letter Another Headache For Pozen

Topics

Advertisement
UsernamePublicRestriction

Register

PS067587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel